← Back to all trials
Not Yet Recruiting
NCT07047508
Real-world Study to Describe the Effectiveness and Safety Outcomes of Jardiance in Chinese Patients With Heart Failure and Preserved Ejection Fraction
Conditions: Heart Failure, Preserved Ejection Fraction
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Enrollment: 3000
Sponsor: Boehringer Ingelheim
Summary
The main objective of the study is to describe the effectiveness and safety outcomes among Chinese hospitalized heart failure with preserved ejection fraction (HFpEF) patients initiating Jardiance® in the real-world setting.
Eligibility Criteria
Inclusion criteria:
* At least 18 years of age
* At least 6 months of data prior to the index date
* Left ventricular ejection fraction (LVEF) \> 40 %
* N-terminal Pro-B-type natriuretic peptide (NT-proBNP) \> 125 pg/mL or brain natriuretic peptide (BNP) ≥ 35 pg/mL
* At least 1 diagnosis of Heart failure with preserved ejection fraction (HFpEF) or Heart failure with mid-range ejection fraction (HFmrEF) or chronic heart failure (CHF) at baseline during the look-back period (on or prior to the index date)
* New users of Jardiance® (initiating Jardiance® on or after March 1st, 2023, and without any record of Jardiance® prescription during the look-back period)
* Body Mass Index (BMI) \
Source: ClinicalTrials.gov (NCT07047508). StuddyBuddy aggregates publicly available trial information.